Latest Media Releases (Page 11) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - Agreement with MD Anderson for Phase 1B CHM 0201 AML study (ASX:CHM)

Investor webinar with the Principal Investigator of the trial, Dr Abhishek Maiti, to be held at 11am AEST Thursday 14 September. Register here. Sydney, Australia, 13 September 2...read more

Immutep - 2023 AGM & Key Dates (ASX:IMM)

SYDNEY, AUSTRALIA – 8 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2023 Annual General M...read more

Immutep to Participate in September Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 6 September 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical stage biotechnology company developing nov...read more

INOVIQ and ResearchDx sign USA EXO-NET Services Agreement (ASX:IIQ)

INOVIQ and ResearchDx sign a license and supply agreement for INOVIQ’s EXO-NET® pan-exosome capture product to provide EXO-NET services in the USA ResearchDx Inc is a...read more

Chimeric Therapeutics - Appendix 4E and Preliminary Final Report (ASX:CHM)

To view the appendix, download the attached PDF.

Radiopharm Theranostics - Appendix 4E and FY23 Financial Report (ASX:RAD)

To view the Appendix 4E and FY23 Financial Report, download the attached PDF.

Next Science - Half Year Report & Appendix 4D (ASX:NXS)

To view the Half Year Report & Appendix 4D, download the attached PDF.

Next Science - Half Year Results & Capital Raise Update (ASX:NXS)

Highlights: - 1HFY23 Product Sales increased 92%yoy to US$10.0m - 1HFY23 Direct Product Sales increased 226% yoy - 1HFY23 Gross Margin of 68% v 81% pcp reflects changing product mix - 1HFY23 U...read more

Next Science - Half Year Results & Capital Raise Presentation (ASX:NXS)

To view the presentation, download the attached PDF.

Paragon Care - FY23 Results Presentation (ASX:PGC)

To view the presentation, download the attached PDF.

Paragon Care - FY23 Results Announcement (ASX:PGC)

Paragon Care Limited (ASX:PGC) (“Paragon Care” or the “Company”) is pleased to report its financial results for the full year ended 30 June 2023 (“FY23”). ...read more

Paragon Care - Appendix 4E and FY23 Financial Statements (ASX:PGC)

To view the Appendix 4E and FY23 Financial Statements, download the attached PDF.

Immutep - Appendix 4E & 2023 Full Year Statutory Accounts (ASX:IMM)

To view the Appendix 4E & 2023 Full Year Statutory Accounts, download the attached PDF.

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the Appendix 4E and Preliminary Financial Report, download the attached PDF.

Chimeric Therapeutics - Dosing completion in Phase 1A brain cancer clinical trial (ASX:CHM)

Treatment of the third clinical trial participant, required to complete the final dose escalation cohort in the CHM 1101 Phase 1A clinical trial, has been completed at City of&n...read more

Viewing: 151 - 165 of 200 Previous | Next